Lucid Capital Markets Starts Coverage on Adlai Nortye, Assigns Buy and $11 Target
Lucid Capital Markets has opened coverage on Adlai Nortye Ltd. (NASDAQ: ANL) with a Buy rating and an $11 price objective, implying roughly 217% upside from the stock's current $3.47 level. The firm highlights the company's pan-RAS inhibitor, AN9025, as the main potential catalyst and models peak non-risk adjusted revenues of about $3.2 billion for…